贝伐珠单抗联合伊立替康与厄洛替尼治疗儿童进展性DIPG的I/II期研究
本研究在9例放疗后进展的儿童弥漫性内生型脑桥胶质瘤(DIPG)患者中,评估贝伐珠单抗、伊立替康联合递增剂量厄洛替尼(65与85 mg/m2)的安全性、耐受性与初步疗效。结果显示联合方案耐受良好,厄洛替尼最大剂量85 mg/m2未再出现剂量限制性毒性,中位总生存期13.8个月,治疗期间整体生活质量稳定。
要点
- 厄洛替尼每日最高85 mg/m2联合贝伐珠单抗与伊立替康在儿童进展性DIPG中安全可耐受。
- 仅第一剂量队列出现1例剂量限制性毒性(III级急性腹泻)。
- 中位总生存期13.8个月,治疗期间整体生活质量稳定。
核心结论
- 每日厄洛替尼最高85 mg/m2联合每两周贝伐珠单抗与伊立替康,在进展性儿童DIPG中安全且耐受良好。
- 研究患者的中位总生存期长于文献已知水平。
研究设计与样本
- I/II期研究,2011年11月至2018年3月入组9例初始放疗后进展的DIPG患儿。
- 每两周贝伐珠单抗10 mg/kg与伊立替康125 mg/m2联合每日厄洛替尼,按3+3剂量递增设计设置65与85 mg/m2两个队列,直至疾病进展,最长治疗一年。
- 每两周监测剂量限制性毒性(DLT),并评估次要无进展生存期(sPFS)、总生存期(OS)与治疗期间生活质量。
主要发现
- 研究开始时中位无进展生存期为7.3个月(范围3.5-10.0)。
- 第一剂量队列1例出现DLT(III级急性腹泻),该队列追加入组3例;后续接受至最高85 mg/m2的患者未再观察到DLT。
- 中位sPFS为3.2个月(范围1.0-10.9),中位OS为13.8个月(范围9.3-33.0)。
- 治疗期间整体生活质量稳定。
临床怎么用
- 对于放疗后进展的儿童DIPG,可考虑厄洛替尼(≤85 mg/m2/日)联合贝伐珠单抗与伊立替康的方案,但需关注腹泻等毒性。
- 该联合方案处于早期研究阶段,样本量小,临床决策应结合个体情况与后续证据。
局限性
- 为单臂I/II期研究,样本量仅9例,无对照组,疗效结论需更大规模研究验证。
- 研究未设正式疗效终点比较,中位OS与文献比较为非随机性推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study investigates the safety, tolerability, and preliminary efficacy of combined treatment with VEGF inhibitor bevacizumab, topoisomerase I inhibitor irinotecan, and EGFR inhibitor erlotinib in children with progressive diffuse intrinsic pontine glioma (DIPG). METHODS: Biweekly bevacizumab (10 mg/kg) and irinotecan (125 mg/m2) were combined with daily erlotinib. Two cohorts received increasing doses of erlotinib (65 and 85 mg/m2) following a 3 + 3 dose-escalation schedule, until disease progression with a maximum of one year. Dose-limiting toxicities (DLT) were monitored biweekly. Secondary progression free survival (sPFS) and overall survival (OS) were determined based on clinical and radiological response measurements. Quality of life (QoL) during treatment was also assessed. RESULTS: Between November 2011 and March 2018, nine patients with disease progression after initial radiotherapy were enrolled. Median PFS at start of the study was 7.3 months (range 3.5-10.0). In the first dose cohort, one patient experienced a DLT (grade III acute diarrhea), resulting in enrollment of three additional patients in this cohort. No additional DLTs were observed in consecutive patients receiving up to a maximum dose of 85 mg/m2. Median sPFS was 3.2 months (range 1.0-10.9), and median OS was 13.8 months (range 9.3-33.0). Overall QoL was stable during treatment. CONCLUSIONS: Daily erlotinib is safe and well tolerated in doses up to 85 mg/m2 when combined with biweekly bevacizumab and irinotecan in children with progressive DIPG. Median OS of the study patients was longer than known form literature.
引用
- El-Khouly FE, Veldhuijzen van Zanten SEM, Jansen MHA, et al. A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma. J Neurooncol. 2021. PMID: 33963476. doi:10.1007/s11060-021-03763-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。